JP2012502649A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502649A5
JP2012502649A5 JP2011527406A JP2011527406A JP2012502649A5 JP 2012502649 A5 JP2012502649 A5 JP 2012502649A5 JP 2011527406 A JP2011527406 A JP 2011527406A JP 2011527406 A JP2011527406 A JP 2011527406A JP 2012502649 A5 JP2012502649 A5 JP 2012502649A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011527406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/051216 external-priority patent/WO2010032059A2/en
Publication of JP2012502649A publication Critical patent/JP2012502649A/ja
Publication of JP2012502649A5 publication Critical patent/JP2012502649A5/ja
Withdrawn legal-status Critical Current

Links

JP2011527406A 2008-09-19 2009-09-18 Cd105を対象とする標的結合剤およびその使用 Withdrawn JP2012502649A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9868508P 2008-09-19 2008-09-19
US61/098,685 2008-09-19
PCT/GB2009/051216 WO2010032059A2 (en) 2008-09-19 2009-09-18 Targeted binding agents directed to cd105 and uses thereof

Publications (2)

Publication Number Publication Date
JP2012502649A JP2012502649A (ja) 2012-02-02
JP2012502649A5 true JP2012502649A5 (https=) 2012-11-01

Family

ID=41263674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527406A Withdrawn JP2012502649A (ja) 2008-09-19 2009-09-18 Cd105を対象とする標的結合剤およびその使用

Country Status (9)

Country Link
US (1) US20100196398A1 (https=)
EP (1) EP2344541A2 (https=)
JP (1) JP2012502649A (https=)
KR (1) KR20110057245A (https=)
CN (1) CN102388067A (https=)
AU (1) AU2009294414A1 (https=)
BR (1) BRPI0918555A2 (https=)
CA (1) CA2737667A1 (https=)
WO (1) WO2010032059A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JP6066912B2 (ja) 2010-10-27 2017-01-25 アムジエン・インコーポレーテツド Dkk1抗体およびその使用方法
CN103619352A (zh) 2011-02-23 2014-03-05 健康研究公司 抗内皮因子抗体和表达新人/鼠嵌合内皮因子的敲入小鼠
EP2681242B1 (en) * 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
HUE041391T2 (hu) * 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
US20130156766A1 (en) * 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
ES2970828T3 (es) 2016-02-10 2024-05-30 Univ Rutgers Nuevos anticuerpos anti-lam
CN117205321A (zh) * 2016-06-14 2023-12-12 西达-赛奈医疗中心 通过内皮糖蛋白拮抗作用使肿瘤对疗法敏感
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
CN108912212B (zh) * 2018-06-28 2019-08-30 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021206636A1 (en) * 2020-04-07 2021-10-14 Agency For Science, Technology And Research ANTIGEN-BINDING PROTEIN TO SARS-CoV-2
CN112426526B (zh) * 2021-01-25 2021-04-06 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
CN112876538B (zh) * 2021-02-04 2022-09-30 福建医科大学 靶向新生血管标记物cd105的多肽及其应用
US12162945B2 (en) 2021-03-05 2024-12-10 Immunome, Inc. EPHA2 antibodies
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
PE20251578A1 (es) * 2022-01-24 2025-06-16 Genovac Antibody Discovery Llc Anticuerpos anti-alk1 y metodos de uso de los mismos
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025045032A1 (zh) * 2023-08-29 2025-03-06 应世生物科技(南京)有限公司 一种靶向cd105的抗体或其抗原结合片段及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
KR20250174161A (ko) * 2024-06-04 2025-12-12 한국과학기술연구원 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
TWI882851B (zh) * 2024-06-27 2025-05-01 蔡政育 基於專利技術元素整合之專利分析系統及其方法
WO2026017807A1 (en) 2024-07-18 2026-01-22 Beech Biotech Sa Compositions and uses thereof
WO2026033033A1 (en) 2024-08-07 2026-02-12 Beech Biotech Sa Compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190660B1 (en) * 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys

Similar Documents

Publication Publication Date Title
JP2012502649A5 (https=)
JP2012525829A5 (https=)
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
JP2013198490A5 (https=)
JP2014526898A5 (https=)
JP2016512551A5 (https=)
JP2014534242A5 (https=)
JP2011526480A5 (https=)
JP2013538057A5 (https=)
JP2015504421A5 (https=)
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
JP2017052784A5 (https=)
JP2014205674A5 (https=)
JP2020504101A5 (https=)
JP2013544756A5 (https=)
JP2015504306A5 (https=)
RU2020129387A (ru) Антитела к pd-1 собак
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2013517330A5 (https=)
JP2010515717A5 (https=)
JP2011517447A5 (https=)
RU2012142230A (ru) Антитела против csf-1r человека и их применение
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
RU2012142231A (ru) Антитела против csf-1r человека и их применение
HRP20191483T1 (hr) Protutijela koja reagiraju s b7-h3, njihovi imunološki aktivni fragmenti i njihova upotreba